AVXL
Anavex Life Sciences Corp. NASDAQ Listed Aug 2, 2006$2.54
-6.96%
vs $2.73
Mkt Cap $216.6M
52w Low $2.46
0.7% of range
52w High $13.41
50d MA $3.00
200d MA $4.97
P/E (TTM)
-5.5x
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.0x
ROE
-31.6%
P/FCF
-5.5x
RSI (14)
34.50
ATR (14)
$0.19
Beta
1.18
50d MA
$3.00
200d MA
$4.97
Avg Volume
1.4M
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
51 West 52nd Street · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | BMO | -0.07 | -0.07 | +0.0% | 2.50 | -0.4% | +0.8% | +6.0% | +2.2% | — | — | — |
| Jun 2, 2026 | BMO | -0.07 | -0.07 | +0.0% | 2.98 | +0.3% | -6.4% | -5.0% | +6.4% | -8.9% | +1.9% | — |
| May 11, 2026 | BMO | — | — | — | 3.22 | -0.9% | +0.6% | -5.6% | +0.7% | +0.0% | -5.5% | — |
| Feb 9, 2026 | BMO | -0.10 | -0.06 | +40.0% | 4.35 | -0.2% | -9.0% | -2.0% | +1.0% | +0.3% | +2.8% | — |
| Nov 25, 2025 | BMO | -0.13 | -0.11 | +15.4% | 3.46 | +2.6% | +11.6% | -0.8% | -0.3% | -3.9% | +24.5% | — |
| Aug 12, 2025 | BMO | -0.13 | -0.16 | -23.1% | 10.78 | -0.3% | -2.0% | -4.3% | -1.6% | -3.6% | -1.6% | — |
| May 13, 2025 | BMO | -0.16 | -0.13 | +18.8% | 8.12 | +1.6% | +0.6% | +2.4% | -0.6% | +1.4% | -10.8% | — |
| Feb 12, 2025 | BMO | -0.17 | -0.14 | +17.6% | 8.70 | +0.0% | -2.6% | +0.6% | +2.1% | +0.2% | -0.5% | — |
| Dec 23, 2024 | BMO | -0.17 | -0.14 | +17.6% | 11.18 | +3.0% | -2.8% | +15.5% | -3.6% | -8.8% | -2.7% | — |
| Aug 6, 2024 | BMO | -0.15 | -0.14 | +6.7% | 6.82 | +2.6% | -10.9% | +9.2% | -5.0% | -2.4% | +4.2% | — |
| May 9, 2024 | BMO | -0.13 | -0.13 | +0.0% | 3.88 | +0.0% | -1.8% | +4.7% | +8.0% | +4.2% | +0.2% | — |
| Feb 7, 2024 | BMO | -0.15 | -0.11 | +26.7% | 5.59 | +1.3% | +1.8% | +1.6% | +6.2% | -9.1% | +4.7% | — |
| Nov 27, 2023 | BMO | -0.16 | -0.12 | +25.0% | 6.36 | +2.7% | +6.6% | +4.6% | +1.7% | +5.0% | +8.3% | — |
| Aug 8, 2023 | BMO | -0.17 | -0.14 | +17.6% | 8.03 | +1.2% | +16.7% | -3.4% | -2.5% | +3.7% | -2.3% | — |
| May 9, 2023 | BMO | -0.18 | -0.17 | +5.6% | 9.07 | +2.8% | +3.2% | -1.8% | -1.0% | +4.3% | -5.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | Rodman & Renshaw | Initiates | Buy | $20 | $3.32 | $3.35 | +0.9% | +2.7% | -1.5% | -0.6% | -6.6% | +3.2% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $2.82 | $2.85 | +1.1% | +8.9% | +1.0% | -3.5% | -1.0% | +4.1% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $2.74 | $2.71 | -1.1% | +5.1% | -2.1% | +0.0% | +8.9% | +1.0% |
| Mar 23 | D. Boral Capital | Maintains | Buy → Buy | — | $4.06 | $4.10 | +1.0% | +9.4% | -5.6% | -34.6% | +5.1% | -2.1% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.35 | $4.34 | -0.2% | -9.0% | -2.0% | +1.0% | +0.3% | +2.8% |
| Feb 9 | D. Boral Capital | Maintains | Buy → Buy | — | $4.10 | $4.20 | +2.4% | +6.1% | -9.0% | -2.0% | +1.0% | +0.3% |
| Jan 6 | D. Boral Capital | Maintains | Buy → Buy | — | $3.95 | $4.13 | +4.6% | +1.5% | +2.2% | +4.1% | +0.2% | +0.2% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.89 | $3.90 | +0.3% | -5.7% | +2.2% | -0.5% | -0.3% | -2.2% |
| Dec 19 | D. Boral Capital | Maintains | Buy → Buy | — | $3.89 | $3.90 | +0.3% | -5.7% | +2.2% | -0.5% | -0.3% | -2.2% |
| Dec 15 | D. Boral Capital | Maintains | Buy → Buy | — | $4.02 | $3.93 | -2.2% | +3.0% | -2.9% | -2.5% | -0.8% | -5.7% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $3.93 | +1.8% | -0.8% | -0.3% | -3.9% | +24.5% | -2.6% |
| Nov 26 | D. Boral Capital | Maintains | Buy → Buy | — | $3.46 | $3.55 | +2.6% | +11.6% | -0.8% | -0.3% | -3.9% | +24.5% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.47 | -0.9% | +2.9% | -11.9% | +2.8% | -5.5% | +12.3% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $5.69 | $2.96 | -48.0% | -35.9% | -1.9% | -2.2% | +2.9% | -11.9% |
| Oct 29 | D. Boral Capital | Maintains | Buy → Buy | — | $8.10 | $8.10 | +0.0% | -1.0% | +0.1% | -0.7% | -2.9% | -3.5% |
| Oct 24 | Jones Trading | Downgrade | Buy → Hold | — | $8.74 | $8.81 | +0.8% | -1.4% | -1.5% | -4.6% | -1.0% | +0.1% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.61 | $9.65 | +0.4% | +1.8% | +0.7% | -3.4% | -2.6% | -7.0% |
| Oct 2 | D. Boral Capital | Maintains | Buy → Buy | — | $9.01 | $9.19 | +2.0% | +1.3% | +9.1% | -3.5% | +1.8% | +0.7% |
| Oct 1 | D. Boral Capital | Maintains | Buy → Buy | — | $8.90 | $8.92 | +0.2% | +1.2% | +1.3% | +9.1% | -3.5% | +1.8% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.26 | $10.28 | +0.2% | -13.5% | +7.9% | -2.2% | -3.0% | -1.4% |
| Sep 10 | D. Boral Capital | Maintains | Buy → Buy | — | $10.26 | $10.28 | +0.2% | -13.5% | +7.9% | -2.2% | -3.0% | -1.4% |
| Aug 27 | D. Boral Capital | Maintains | Buy → Buy | — | $9.53 | $9.37 | -1.7% | -0.8% | -2.4% | +4.6% | -1.7% | +0.3% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.55 | $9.50 | -0.5% | -0.2% | -1.4% | +1.4% | -0.8% | -2.4% |
| Aug 13 | D. Boral Capital | Maintains | Buy → Buy | — | $10.78 | $10.75 | -0.3% | -2.0% | -4.3% | -1.6% | -3.6% | -1.6% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $11.20 | $11.09 | -1.0% | -3.4% | +0.6% | +0.7% | +2.3% | -1.2% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.19 | $7.89 | -3.7% | +1.7% | -8.8% | +14.7% | -2.1% | +3.7% |
| Apr 7 | D. Boral Capital | Maintains | Buy → Buy | — | $8.19 | $7.89 | -3.7% | +1.7% | -8.8% | +14.7% | -2.1% | +3.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.72 | $8.41 | -3.6% | -1.6% | -6.5% | +6.7% | -3.0% | -1.3% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.54 | +0.2% | +2.1% | +0.2% | -0.5% | -3.8% | -1.1% |
| Feb 12 | D. Boral Capital | Maintains | Buy → Buy | — | $8.29 | $8.05 | -2.9% | +4.9% | -2.6% | +0.6% | +2.1% | +0.2% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $9.82 | $9.87 | +0.5% | +0.9% | -2.1% | -1.3% | -3.1% | -6.8% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.82 | $9.87 | +0.5% | +0.9% | -2.1% | -1.3% | -3.1% | -6.8% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.21 | $9.25 | +0.4% | +6.9% | +1.4% | +2.1% | +2.8% | -6.4% |
| Jan 15 | D. Boral Capital | Maintains | Buy → Buy | — | $10.47 | $10.70 | +2.2% | +8.2% | -10.4% | -9.3% | +6.9% | +1.4% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $11.23 | $11.02 | -1.9% | -6.1% | -0.8% | +8.2% | -10.4% | -9.3% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.87 | $10.84 | -0.3% | +15.5% | -3.6% | -8.8% | -2.7% | +13.1% |
| Dec 23 | D. Boral Capital | Maintains | Buy → Buy | — | $8.63 | $8.92 | +3.4% | +29.5% | -2.8% | +15.5% | -3.6% | -8.8% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.04 | $9.09 | +0.6% | -0.1% | +4.8% | -1.5% | -3.6% | +0.9% |
| Nov 26 | D. Boral Capital | Maintains | Buy → Buy | — | $9.13 | $10.30 | +12.8% | -1.0% | -0.1% | +4.8% | -1.5% | -3.6% |
| Nov 25 | D. Boral Capital | Maintains | Buy → Buy | — | $9.11 | $9.52 | +4.5% | +0.2% | -1.0% | -0.1% | +4.8% | -1.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.84 | $6.82 | -0.3% | +6.7% | +5.5% | +1.2% | -1.9% | +20.9% |
| Oct 31 | EF Hutton | Maintains | Buy → Buy | — | $5.71 | $5.88 | +3.0% | +15.9% | +3.3% | +6.7% | +5.5% | +1.2% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.51 | $5.52 | +0.2% | +2.5% | -3.5% | +3.5% | -4.4% | -1.1% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.77 | -0.4% | -3.2% | -1.2% | -0.8% | +5.7% | -10.9% |
| Jul 29 | EF Hutton | Maintains | Buy → Buy | — | $6.74 | $7.00 | +3.9% | +4.5% | -10.4% | +7.8% | -3.2% | -1.2% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $3.75 | -1.1% | -2.4% | +1.4% | -0.5% | +1.1% | -1.1% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $3.88 | +0.0% | -1.8% | +4.7% | +8.0% | +4.2% | +0.2% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.05 | $6.09 | +0.7% | +7.9% | -3.7% | -4.5% | +9.2% | -2.3% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $6.53 | +2.7% | +6.6% | +4.6% | +1.7% | +5.0% | +8.3% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $8.00 | +4.2% | +4.6% | +16.7% | -3.4% | -2.5% | +3.7% |
No insider trades available.
8-K · 8.01
!! High
Anavex Life Sciences Corp. -- 8-K 8.01: Material Event / Announcement
May 22
NT 10-Q
!! High
Anavex Life Sciences Corp. -- Late Quarterly Report -- Distress Signal
May 11
8-K · 5.02
!!! Very High
Anavex Life Sciences Corp. -- 8-K 5.02: Executive Change
Anavex Life Sciences named Terrie Kellmeyer interim CEO following Christopher Missling's resignation, though Kellmeyer simultaneously resigned from the same position, creating leadership uncertainty.
May 6
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Anavex Life Sciences' withdrawn EMA application for blarcamesine signals regulatory setbacks that delay European market access and increase development timelines, pressuring near-term revenue prospects.
Mar 25
8-K · 5.02
!!! Very High
Anavex Life Sciences -- 8-K 5.02: Executive Change
Anavex Life Sciences appointed Axel Paeger as director effective February 23, 2026, potentially signaling leadership changes that investors should monitor for strategic implications.
Feb 25
8-K
Anavex Life Sciences -- 8-K Filing
Anavex Life Sciences reported Q1 fiscal 2026 results and provided a business update, with management hosting a webcast to discuss the clinical-stage biotech company's financial performance and strategic developments.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 3,863,950 | $12M | New | Mar 2026 |
| 2 | Two Sigma Investments, Lp | 3,247,888 | $10M | Added | Mar 2026 |
| 3 | Nwam Llc | 874,283 | $8M | Reduced | Sep 2025 |
| 4 | Morgan Stanley | 949,712 | $3M | Reduced | Dec 2025 |
| 5 | Susquehanna International Group, Llp | 995,663 | $3M | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 768,955 | $3M | Added | Dec 2025 |
| 7 | Bank Of America Corp /de/ | 863,150 | $3M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 783,148 | $2M | New | Mar 2026 |
| 9 | Aqr Capital Management Llc | 756,792 | $2M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 725,187 | $2M | Reduced | Mar 2026 |
| 11 | Hrt Financial Lp | 657,877 | $2M | New | Mar 2026 |
| 12 | Ubs Group Ag | 569,956 | $2M | Added | Mar 2026 |
| 13 | Citadel Advisors Llc | 559,435 | $2M | Added | Mar 2026 |
| 14 | Barclays Plc | 538,277 | $2M | Added | Mar 2026 |
| 15 | Private Advisor Group, Llc | 499,700 | $2M | Added | Mar 2026 |
| 16 | Marshall Wace, Llp | 419,497 | $1M | Added | Mar 2026 |
| 17 | Caption Management, Llc | 354,838 | $1M | New | Dec 2025 |
| 18 | Renaissance Technologies Llc | 276,800 | $850K | Added | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 247,849 | $761K | Added | Mar 2026 |
| 20 | Eversource Wealth Advisors, Llc | 5,023 | $663K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$216.6M
Enterprise Value
$114.1M
P/E (TTM)
-5.48x
Forward P/E
—
PEG Ratio
-4.26x
P/B
2.28x
P/S
—
P/FCF
-5.55x
EV/EBITDA
—
Shares Out
85.3M
Financials (TTM)
Revenue
$0
Net Income
-$39.9M
EBITDA
-$38.9M
Free Cash Flow
-$39.0M
Op Cash Flow
-$39.0M
EPS Basic
$-0.54
EPS Diluted
$-0.46
EPS Forward
$-0.33
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$103.8M
Total Liab.
$8.9M
Total Equity
$94.9M
Cash
$102.6M
LT Debt
$0
Book Value/Sh
$1.11
Debt/Equity
0.00x
Current Ratio
11.60
Quick Ratio
11.60
Returns & Growth
ROE
-31.6%
ROA
-30.0%
ROIC
-54.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
-3.9%
Price Returns
2W
-1.6%
1M
-9.3%
3M
-31.6%
6M
-20.9%
12M
-59.8%
Technicals
52W High
$13.41
52W Low
$2.46
50d MA
$3.00
200d MA
$4.97
RSI (14)
34.50
ATR (14)
$0.19
Beta
1.18
Avg Volume
1.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$11.00
Low
$11.00
Median
$11.00
Data updated apr 24, 2026 8:05pm
· Source: financialmodelingprep.com